logo-loader
viewAvacta Group PLC

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst Ed Stacey

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space.

The group's reported interim results to January 2019 today, revealing revenues of £1.0mln and illustrating good progress on its key development programmes.

Quick facts: Avacta Group PLC

Price: 22.75 GBX

AIM:AVCT
Market: AIM
Market Cap: £40.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bulls, Bears and Brokers: Alto Capital’s Tony Locantro picks five...

Alto Capital investment manager and stock market commentator Tony Locantro speaks to Proactive about the stock markets reaction to the Dow Jones crash as well as the top five investments to look out for this week.  Locantro also provides his views on the real-estate markets'...

in 57 minutes

2 min read